Real life use of natalizumab and fingolimod - data from the nation-wide Austrian Multiple Sclerosis Treatment Registry

M Guger; C Enzinger; F Leutmezer; Johannes Kraus; T Berger

Real life use of natalizumab and fingolimod - data from the nation-wide Austrian Multiple Sclerosis Treatment Registry

M Guger, C Enzinger, F Leutmezer, Johannes Kraus, T Berger

Department of Internal Medicine II - Division of Cardiology

Research output: Contribution to journal › Abstract (Journal) › peer-review

Original language	English
Pages (from-to)	315-316
Journal	MULTIPLE SCLEROSIS
Volume	23
Publication status	Published - 2017
Event	7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS) - Paris, FRANCE Duration: 25 Oct 2017 → 28 Oct 2017

Cite this

Guger, M., Enzinger, C., Leutmezer, F., Kraus, J., & Berger, T. (2017). Real life use of natalizumab and fingolimod - data from the nation-wide Austrian Multiple Sclerosis Treatment Registry. MULTIPLE SCLEROSIS , 23, 315-316.

Guger, M ; Enzinger, C ; Leutmezer, F et al. / Real life use of natalizumab and fingolimod - data from the nation-wide Austrian Multiple Sclerosis Treatment Registry. In: MULTIPLE SCLEROSIS 2017 ; Vol. 23. pp. 315-316.

@article{b512a22adcb043a1b15fae6b3cfcd219,

title = "Real life use of natalizumab and fingolimod - data from the nation-wide Austrian Multiple Sclerosis Treatment Registry",

author = "M Guger and C Enzinger and F Leutmezer and Johannes Kraus and T Berger",

year = "2017",

language = "English",

volume = "23",

pages = "315--316",

journal = "MULTIPLE SCLEROSIS ",

issn = "1352-4585",

note = "7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS) ; Conference date: 25-10-2017 Through 28-10-2017",

}

Guger, M, Enzinger, C, Leutmezer, F, Kraus, J & Berger, T 2017, 'Real life use of natalizumab and fingolimod - data from the nation-wide Austrian Multiple Sclerosis Treatment Registry', MULTIPLE SCLEROSIS , vol. 23, pp. 315-316.

Real life use of natalizumab and fingolimod - data from the nation-wide Austrian Multiple Sclerosis Treatment Registry. / Guger, M; Enzinger, C; Leutmezer, F et al.
In: MULTIPLE SCLEROSIS , Vol. 23, 2017, p. 315-316.

Research output: Contribution to journal › Abstract (Journal) › peer-review

TY - JOUR

T1 - Real life use of natalizumab and fingolimod - data from the nation-wide Austrian Multiple Sclerosis Treatment Registry

AU - Guger, M

AU - Enzinger, C

AU - Leutmezer, F

AU - Kraus, Johannes

AU - Berger, T

PY - 2017

Y1 - 2017

M3 - Abstract (Journal)

SN - 1352-4585

VL - 23

SP - 315

EP - 316

JO - MULTIPLE SCLEROSIS

JF - MULTIPLE SCLEROSIS

T2 - 7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS)

Y2 - 25 October 2017 through 28 October 2017

ER -

Guger M, Enzinger C, Leutmezer F, Kraus J, Berger T. Real life use of natalizumab and fingolimod - data from the nation-wide Austrian Multiple Sclerosis Treatment Registry. MULTIPLE SCLEROSIS . 2017;23:315-316.